Substantial adverse effects, even patient's death, and resistance to currently widely used drugs in the treatment of cancer, cardiovascular and other major disease still remains a big problem in public health including costs. Pharmacogenomics, a rapidly growing part of genomics, provides promises genome sequencing-based identification of genetic variants that may predict sensitivity and adverse events of drugs in individual patients. Here, I describe the latest advances, the limitations in routine clinical practice and the challenges to overcome to reach the optimal prescription of drugs depending on individuality due to pharmacogenomics.
(Citation: Gastric & Breast Cancer 2011; 10(4) 256-261)
is 7 pages long.